What is Hexarelin?
Hexarelin (also known as Examorelin) is a synthetic hexapeptide growth hormone releasing peptide (
Hexarelin — synthetic GHRP with stronger activity than GHRP-6
In short
Modified GHRP class peptide studied as a potent stimulator of growth hormone via GHS-R1a receptor activation.
Overview
Hexarelin (also known as Examorelin) is a synthetic hexapeptide growth hormone releasing peptide (
Binds to ghrelin receptor (GHS-R1a) on pituitary somatotrophs to stimulate pulsatile release. Also activates cardiac CD36 receptors providing -independent cardioprotection through anti-apoptotic and anti-fibrotic mechanisms.
Molecular information
First-order decay curve at 1.2h half-life from literature. Educational only.
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Strongest in class - appropriate when maximum amplitude is needed. Cortisol/prolactin elevation 30-50% is the tradeoff.
Hexarelin е най-мощният , но има най-изразен профил на странични ефекти в групата. Повишава нивата на кортизол и пролактин при стандартни дози, за разлика от Ipamorelin. Може да причини задържане на вода, особено през първите 1-2 седмици. Влияе върху метаболизма на глюкозата. Проследявайте състоянието при диабет или преддиабет. Не е подходящ за лица с активен рак поради ефектите върху растежа. Hexarelin е забранен от WADA в състезателния спорт. Продължителната употреба може да доведе до вторичен хипогонадизъм поради повишения пролактин. Частичната десенсибилизация е нормална и обратима при циклично приложение. Прекратете употребата при постоянна болка в ставите или симптоми на карпален тунел. Спрете при тежко задържане на вода или оток, който не преминава след 2 седмици. Прекратете при признаци на гинекомастия, значителна умора или дисрегулация на кръвната захар. Спрете приложението при необяснимо главоболие, зрителни промени или признаци на алергична реакция на мястото на инжектиране.
4 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Imbimbo - Single dose
Clinical | 2 mcg/kg | single | GH +10-20x baseline
Eur J Endocrinol · 1994
View the studyInformation about Hexarelin is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.